Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Warning time and patient centred goals with transdermal oxybutynin.

Trial Profile

Warning time and patient centred goals with transdermal oxybutynin.

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2014

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms WTPCGTO
  • Most Recent Events

    • 27 Jul 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
    • 12 Jul 2011 Trial phase changed from II to IV as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top